III期肺癌-话题@MedSci

#III期肺癌#

8篇内容 | 996人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2214415, encodeId=eace221441588, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a> <a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a> <a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, objectTitle=III期肺癌放化疗和免疫治疗前后ctDNA分组，活过2年的比例差2倍！, objectType=article, longId=832465, objectId=698283246584, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240711/1720668245753_5579292.png, objectUrl=/article/show_article.do?id=698283246584, replyNumber=0, likeNumber=54, createdTime=2024-07-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=698283246584, moduleTitle=III期肺癌放化疗和免疫治疗前后ctDNA分组，活过2年的比例差2倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=698283246584)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2034077, encodeId=c41420340e70c, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, objectTitle=GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？, objectType=article, longId=727255, objectId=541de2725547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541de2725547, replyNumber=0, likeNumber=70, createdTime=2022-07-02, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541de2725547, moduleTitle=GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=541de2725547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034076, encodeId=c4ec20340e62a, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, objectTitle=江西首家III期肺癌多学科规范化诊疗中心成立, objectType=article, longId=194358, objectId=f3e51943580e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3e51943580e, replyNumber=0, likeNumber=58, createdTime=2020-12-02, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3e51943580e, moduleTitle=江西首家III期肺癌多学科规范化诊疗中心成立, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3e51943580e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034075, encodeId=962720340e513, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, objectTitle=喜大普奔！中国PD-L1免疫疗法惠及III期肺癌患者，5年生存率或超50%, objectType=article, longId=189360, objectId=4814189360cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4814189360cb, replyNumber=0, likeNumber=80, createdTime=2020-06-13, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4814189360cb, moduleTitle=喜大普奔！中国PD-L1免疫疗法惠及III期肺癌患者，5年生存率或超50%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4814189360cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034074, encodeId=bee620340e4da, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, objectTitle=国内III期肺癌规范化诊疗示范中心正式成立，精准助力III期肺癌规范化诊疗, objectType=article, longId=180140, objectId=317118014061, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317118014061, replyNumber=0, likeNumber=65, createdTime=2019-11-02, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317118014061, moduleTitle=国内III期肺癌规范化诊疗示范中心正式成立，精准助力III期肺癌规范化诊疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=317118014061)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034073, encodeId=314720340e3f6, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, objectTitle=PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光, objectType=article, longId=176064, objectId=15841e606424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15841e606424, replyNumber=0, likeNumber=67, createdTime=2019-12-13, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15841e606424, moduleTitle=PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15841e606424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034072, encodeId=066520340e2dc, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, objectTitle=樊旼教授：PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光, objectType=article, longId=176018, objectId=5b4a1e6018c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b4a1e6018c7, replyNumber=0, likeNumber=63, createdTime=2019-09-24, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b4a1e6018c7, moduleTitle=樊旼教授：PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b4a1e6018c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034071, encodeId=812b20340e139, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, objectTitle=GSK实验性MAGE-A3免疫疗法III期肺癌研究失败, objectType=article, longId=32199, objectId=5cc332199eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cc332199eb, replyNumber=0, likeNumber=72, createdTime=2014-11-10, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cc332199eb, moduleTitle=GSK实验性MAGE-A3免疫疗法III期肺癌研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cc332199eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2034070, encodeId=dc7720340e068, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, objectTitle=罗氏抗癌药MetMab III期肺癌研究受挫, objectType=article, longId=31466, objectId=bba93146612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bba93146612, replyNumber=0, likeNumber=72, createdTime=2014-04-30, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bba93146612, moduleTitle=罗氏抗癌药MetMab III期肺癌研究受挫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bba93146612)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期肺癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#同步放化疗# #PD-L1# #III期肺癌#

III期肺癌放化疗和免疫治疗前后ctDNA分组，活过2年的比例差2倍！

2024-07-11发表于上海

amy0550 (审核中...)

前往app查看评论内容

#III期肺癌#

GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？

2022-07-02

amy0550 (审核中...)

前往app查看评论内容

#III期肺癌#

江西首家III期肺癌多学科规范化诊疗中心成立

2020-12-02

amy0550 (审核中...)

前往app查看评论内容

#III期肺癌#

喜大普奔！中国PD-L1免疫疗法惠及III期肺癌患者，5年生存率或超50%

2020-06-13

amy0550 (审核中...)

前往app查看评论内容

#III期肺癌#

国内III期肺癌规范化诊疗示范中心正式成立，精准助力III期肺癌规范化诊疗

2019-11-02

amy0550 (审核中...)

前往app查看评论内容

#III期肺癌#

PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光

2019-12-13

amy0550 (审核中...)

前往app查看评论内容

#III期肺癌#

樊旼教授：PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光

2019-09-24

amy0550 (审核中...)

前往app查看评论内容

#III期肺癌#

GSK实验性MAGE-A3免疫疗法III期肺癌研究失败

2014-11-10

amy0550 (审核中...)

前往app查看评论内容

#III期肺癌#

罗氏抗癌药MetMab III期肺癌研究受挫

2014-04-30

科室
- - 订阅+
  - 更多科室
工具
服务